Document: NUREG-0800
Document ID: 49aefb86-1adb-4b3c-826f-480e32947595
Document Type: srp
Title: Radiological Consequence Analyses Using Alternative Source Terms
Source: NUREG-0800
Source URL: https://www.nrc.gov/docs/ML0037/ML003734190.pdf
Revision Date: 2023-06
Chapter: 15
Section ID: 15.0.1
CFR Part: 
CFR Title: 

Content:
t assumption in conjunction with the proposed modification creates a concern regarding adequate protection of the public. c. Independent calculations should be performed as necessary to conclude, with reasonable assurance, that the applicant’s analyses are acceptable. The staff’s approval of the application is to be based on the licensee’s docketed information. If differences are discovered between the licensee’s methods and assumptions and those deemed acceptable to the staff, the reviewer should resolve the differences with the licensee. If necessary, the licensee should update the disputed assumptions and resubmit the affected analyses. d. The radiation doses postulated for the EAB, the LPZ, and the control room are compared to the acceptance criteria in Section II of this SRP section. 7. The analyses of radiological doses associated with the applicable NUREG-0737 items identified in Section I are evaluated against the guidance provided in NUREG-0737 and in any license commitments related to these items. The dose criterion for these items is generally derived from the GDC-19 criteria. As GDC-19 has been updated to 5 rem TEDE, the dose criterion for NUREG-0737 items should also be 5 rem TEDE. 8. Evaluations of integrated radiation doses associated with equipment qualification are performed by EELB using the guidance of Regulatory Guide 1.89 (Ref. 6), supplemented by Appendix I to RG-1.183. The NRC staff is assessing the effect of increased cesium releases on EQ doses to determine if licensee action is warranted. Until such time as this generic issue is resolved, licensees may use either the AST or the TID14844 assumptions for performing the required EQ analyses. However, no plant modifications are required to address the impact of the difference in source term characteristics (i.e., AST vs TID14844) on EQ doses pending the outcome of the evaluation of the generic issue. 9. Licensees may propose changes in the period over which EQ dose estimates are